Indication:
Empirical therapy for presumed fungal infection in febrile, neutropenic patients;
Treatment of cryptococcal meningitis in HIV-infected patients;
Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections and treatment of visceral leishmaniasis.
Strength: 50mg
Innovator: Gilead Sciences Ireland UC
Innovative Brand: AmBisome
Qualification: To be approved in: (2024.10). Under priority review in Turkey
Registering in Saudi Arabia
Key selling points: 
1. Broad applicability: This product is suitable for the treatment of various deep fungal infections, such as candidiasis and cryptococcosis, meeting the therapeutic needs of different patients. 
2. Liposomal formulations can mitigate cardiac toxicity, bone marrow suppression, and alopecia, among other side effects, thereby enhancing patients' tolerability and quality of life.